

学位論文

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

**Role of Glial Cells in Regulating Retinal Blood Flow during  
Flicker-Induced Hyperemia in Cats**

(フリッカー光刺激後の網膜血流増加反応における Glia 細胞の役割)

旭川医科大学大学院医学系研究科博士課程医学専攻

宋 勇錫

---

(長岡泰司, 善岡尊文, 中林征吾, 谷智文, 吉田晃敏と共著)

32 **Role of Glial Cells in Regulating Retinal Blood Flow during Flicker-Induced**

33 **Hyperemia in Cats**

34

35 *Youngseok Song, Taiji Nagaoka,\* Takafumi Yoshioka, Seigo Nakabayashi,*

36 *Tomofumi Tani, and Akitoshi Yoshida*

37

38 From the Department of Ophthalmology, Asahikawa Medical University, Asahikawa,  
39 Japan.

40

41 **Running title: Glial Cell Role in Retinal Blood Flow**

42

43 Corresponding author: Taiji Nagaoka, MD, PhD, Department of Ophthalmology,  
44 Asahikawa Medical University, Midorigaoka Higashi 2-1-1-1, Asahikawa, 078-8510,  
45 Japan; phone: +81-166-68-2543; fax: +81-166-68-2549; E-mail:  
46 nagaoka@asahikawa-med.ac.jp.

47

48 Supported by a Grant-in-Aid for Scientific Research (B) 25293352 and  
49 Challenging Exploratory Research 25670724 from the Ministry of Education, Science,  
50 and Culture, Tokyo, Japan (to TN) and a Grant-in-Aid for Scientific Research (B)  
51 26861430 from the Ministry of Education, Science, and Culture, Tokyo, Japan (to YS)

52

53 **Word count: 4,259 words**

54 The authors have no financial/conflicting interests to disclose.

55

56 **ABSTRACT**

57 **PURPOSE.** To investigate how glial cells participate in retinal circulation during flicker  
58 stimulation in cats.

59 **METHODS.** Using laser Doppler velocimetry, we measured the vessel diameter and  
60 blood velocity simultaneously and calculated the retinal blood flow (RBF) in feline  
61 first-order retinal arterioles. Twenty-four hours after intravitreal injections of  
62 L-2-aminoadipic acid (LAA), a gliotoxic compound, and the solvent of 0.01 N  
63 hydrochloric acid as a control, we examined the changes in RBF in response to 16-Hz  
64 flicker stimulation for 3 minutes. We also measured the changes in RBF 2 hours after  
65 intravitreal injection of N $\omega$ -propyl-L-arginine (L-NPA), a selective neuronal nitric  
66 oxide synthase inhibitor, in LAA-treated eyes. To evaluate the effects of LAA on retinal  
67 neuronal function, electroretinograms (ERGs) were monitored. Immunohistochemical  
68 examinations were performed.

69 **RESULTS.** In LAA-treated eyes, histologic changes selectively occurred in retinal glial  
70 cells. There were no significant reductions in amplitude or elongation of implicit time in  
71 ERG after LAA injections compared with controls. In control eyes, the RBF gradually  
72 increased and reached the maximal level ( $53.5 \pm 2.5\%$  increase from baseline) after 2 to  
73 3 minutes of flicker stimulation. In LAA-treated eyes, the increases in RBF during  
74 flicker stimulation were attenuated significantly compared with controls. In  
75 LAA-treated eyes 2 hours after injection of L-NPA, flicker-evoked increases in RBF  
76 decreased significantly compared with LAA-treated eyes.

77 **CONCLUSIONS.** The current results suggested that increases in RBF in response to  
78 flicker stimulation were regulated partly by retinal glial cells.

79

80 **Keywords.**

81 retinal blood flow, flicker induced hyperemia, retinal glial cells, gliotoxic compound,

82 neurovascular coupling

83

84 **Précis**

85 The reduction in the flicker-evoked increase in retinal circulation after intravitreal

86 injection of gliotoxic compound in cats suggests that retinal glial cells are involved in the

87 regulation of the retinal circulation during flicker stimulation.

88

89 To maintain neuronal function, the brain has evolved neurovascular coupling  
90 mechanisms to increase the regional blood flow, which Roy and Sherrington referred to  
91 as functional hyperemia, when they first described this concept more than a century  
92 ago.<sup>1,2</sup> Retinal vessels dilate and retinal blood flow (RBF) increases as a result of the  
93 functional hyperemic response when the retina is stimulated by a flickering light,  
94 indicating that the retinal neural activity is associated with blood flow and metabolism,  
95 and considered as metabolic autoregulation in the retinal circulation.<sup>3,4</sup>

96 Metabolic autoregulation in neurovascular coupling is maintained by three major  
97 cells, i.e., neurons, vasculature, and glial cells, in the brain and the retina.<sup>2,5,6</sup> Glial cells,  
98 including Müller cells and astrocytes as the main glial cells in the retina,<sup>7</sup> are vital for  
99 maintaining normal retinal function.<sup>8</sup> Recent evidence from an animal experiment  
100 indicates that glial cells play a principal role in coupling neuronal activity to vessel  
101 dilation in retinal functional hyperemia.<sup>6</sup> Indeed, impaired glial cell activity may be  
102 related to the pathological mechanisms of ocular disorders such as diabetic retinopathy  
103 (DR) and glaucoma.<sup>9-12</sup> Moreover, some clinical studies have reported that vasodilation  
104 of the retinal vessels elicited by flicker stimuli deteriorates in patients with these  
105 diseases.<sup>13-15</sup> However, the involvement of glial cells in regulating the RBF in response  
106 to flicker stimulation has not been well determined.<sup>16</sup> Although some reports have  
107 focused on the role of glial cells in metabolic autoregulation in neurovascular  
108 coupling,<sup>2,6,16-18</sup> the role in the retinal vasculature remains unclear.

109 In previous studies, L-2-amino adipic acid (LAA),<sup>17,19,20</sup> a gliotoxic compound,  
110 was injected intravitreally to examine the specific role of glial cells in the retina. We  
111 investigated the role of retinal glial cells in regulating the RBF in response to flicker

112 stimulation after suppressing the retinal glial cell function with intravitreal injection of  
113 LAA in cats.

114

## 115 **MATERIALS AND METHODS**

### 116 **Animal Preparation**

117 The Animal Care Committee of Asahikawa Medical University approved the study  
118 protocols in cats; the study adhered to the ARVO Statement for the Use of Animals in  
119 Ophthalmic and Vision Research. Thirty-six adult cats (2.6-3.2 kg) of either sex were  
120 tracheostomized and mechanically ventilated with room air containing 2% sevoflurane.  
121 The flow rate of sevoflurane was maintained at 1.5 L/minute during the experiment.  
122 Catheters were placed in the femoral arteries and vein. The mean arterial blood pressure  
123 (MABP) and heart rate (HR) were monitored continuously with a transducer (PowerLab,  
124 ADInstruments, Inc., Colorado Springs, CO) and recorder (LabChart, ADInstruments  
125 Inc.) in the proximal thoracic descending aorta. Pancuronium bromide (0.1 mg/kg/h)  
126 (Daiichi Sankyo Co., Tokyo, Japan) was infused continuously via the femoral vein to  
127 maintain skeletal muscle relaxation. With the animal prone, the head was fixed in a  
128 stereotaxic instrument. The arterial pH (pH), arterial partial carbon dioxide tension  
129 ( $\text{PaCO}_2$ ), arterial partial oxygen tension ( $\text{PaO}_2$ ), and bicarbonate ion ( $\text{HCO}_3^-$ ) were  
130 measured intermittently with a blood gas analyzer (model ABL5, Radiometer,  
131 Copenhagen, Denmark). The rectal temperature was measured and maintained between  
132 37° and 38 °C with a heated blanket. The pupils were dilated with 0.4% tropicamide  
133 (Santen Pharmaceutical Co., Osaka, Japan). A 0-diopter contact lens (Seed Co. Ltd.,  
134 Tokyo, Japan) was placed on the cornea, which was protected by instillation of a drop  
135 of sodium hyaluronate (Healon, Abbott Medical Optics, Inc., Abbott Park, IL). A

136 26-gauge butterfly needle was inserted into the anterior chamber and connected to a  
137 pressure transducer and a balanced salt solution (Alcon, Fort Worth, TX) reservoir for  
138 monitoring and maintaining the intraocular pressure (IOP) at a constant level of 10  
139 mmHg, respectively. Table 1 shows the systemic and ocular parameters at rest.

#### 140 **RBF Measurements**

141 A laser Doppler velocimetry (LDV) system (Laser Blood Flowmeter, model 100, Canon,  
142 Inc., Tokyo, Japan) customized for feline use was used to measure the retinal arteriolar  
143 diameter (D) (in micrometers) and velocity (V) (millimeters/second) as described  
144 previously.<sup>21,22</sup> The RBF in the arterioles (microliters/minute) was calculated based on  
145 the acquired V and D. Laser Doppler measurements of the temporal retinal arterioles  
146 were performed in one eye of each animal. The first-order arterioles were chosen for  
147 study because they have relatively straight segments and were sufficiently distant from  
148 the adjacent vessels for consistent measurements.

149 The RBF was calculated using the formula  $RBF = S \times V_{\text{mean}}$ , where S is the  
150 cross-sectional area of the retinal arteriole at the laser Doppler measurement site,  
151 assuming a circular cross-section, and  $V_{\text{mean}}$  is the mean blood V calculated as  $V_{\text{mean}}$   
152  $= V_{\text{max}}/2$ .<sup>23</sup> The MABP was determined using the formula  $MABP = \text{diastolic BP} +$   
153  $(\text{systolic BP} - \text{diastolic BP})/3$ , which is the index of the systemic BP. Because the cats  
154 were prone during the experiments, the ocular perfusion pressure (OPP) was calculated  
155 as  $OPP = MABP - IOP$ .<sup>24,25</sup>

#### 156 **Flicker Stimulation**

157 As we showed previously,<sup>26</sup> we used 16-Hz stimuli as flicker stimulation because the  
158 frequency obtained a maximal RBF response in cats and the eyes were allowed to  
159 dark-adapt for 2 hours before flicker stimuli.<sup>26</sup> Fundus illumination was used only for

160 alignment before dark adaptation started. The detailed protocol and instruments used in  
161 flicker stimulation were described previously.<sup>26</sup>

### 162 **Intravitreal Injections and Chemicals**

163 A 30-gauge needle (100- $\mu$ L syringe; Hamilton, Reno, NV) was used for the intravitreal  
164 injections (3 mm posterior to the limbus) with care taken not to injure the lens and  
165 retina.<sup>21</sup> The head of the needle was positioned over the optic disc region. LAA and  
166 bradykinin (BK) were purchased from Sigma Chemical Co. (St. Louis, MO).  
167 N $\omega$ -propyl-L-arginine (L-NPA) was obtained from Cayman Chemicals Co. (Ann  
168 Arbor, MI). The drugs without LAA were dissolved in phosphate buffered saline (PBS).  
169 LAA was dissolved in 0.01 N hydrochloric acid (HCl) because LAA does not dissolve  
170 in PBS. The volume of the intravitreal injections was 50  $\mu$ l, which does not alter retinal  
171 circulatory parameters and minimizes the systemic effects of the inhibitors.<sup>21</sup> Because  
172 the cat vitreous is about 2.5 mL, the 50- $\mu$ l solution injected into the vitreous cavity is  
173 diluted by a factor of 50 near the retinal vessels. Hereafter, we refer to drug  
174 concentrations as injected concentrations.

175 The 20 and 60 mM LAA concentrations (final concentrations in the vitreous  
176 cavity of 0.4 and 1.2 mM, respectively) were chosen because 1.25 mM L-2-aminoadipic  
177 acid causes swelling of the Müller cells and astrocytes while the remaining neural cells  
178 remain intact.<sup>27</sup> The 24-hour time course after intravitreal injection of LAA was chosen  
179 because pathologic changes and dysfunction on the electroretinograms (ERGs) were not  
180 observed in the neural retina, although the Müller cells had some damage, i.e., pale  
181 stained nuclei and increased glycogen granules 24 hours after the LAA injections.<sup>17,27</sup>

### 182 **Changes in RBF to Flicker Stimulation**

183 The measurements of D and V were started 5 minutes before flicker stimulation. The  
184 mean of five measurements at 1-minute intervals was recorded as the baseline value.  
185 The retina then was stimulated by the flickering light and the RBF measurements were  
186 performed every 30 seconds during the stimulation period. The changes in the retinal  
187 circulatory parameters were expressed as the percent change from baseline. In the  
188 current study, because the blood flow reaches a plateau 2 minutes after flicker  
189 stimulation, in the current study, we expressed the average value of three points of 120  
190 to 180 seconds as the maximal change.<sup>26</sup> To assess whether LAA suppresses  
191 flicker-induced hyperemia in the retinal arterioles, we evaluated the changes in the RBF  
192 in response to flicker stimuli 24 hours after intravitreal injections of LAA or 0.01 N HCl  
193 as a control.

#### 194 **Effects of Gliotoxic Compound on Increased RBF in Response to BK**

195 Because we confirmed previously that BK causes endothelium-dependent, nitric oxide  
196 (NO)-mediated vasodilation in isolated porcine retinal arterioles,<sup>28</sup> we injected BK into  
197 the vitreous to cause the endothelium-dependent vasodilation.<sup>29</sup> The increase in RBF  
198 induced by intravitreal injections of BK (50  $\mu$ M) reached the maximal level at 120  
199 minutes and persisted for at least 3 hours in our previous study.<sup>29</sup> These concentrations  
200 were sufficient for the maximal vasodilation concentrations of BK, based on our  
201 previous in vitro study.<sup>28</sup>

202 To assess the effect of LAA on endothelial vasodilatory function in the changes in  
203 the RBF in response to intravitreal injection of BK, the RBF was measured before and 2  
204 hours after intravitreal injection of BK with pre-treatment with LAA (20 mM, 60 mM)  
205 or 0.01 N HCl as a vehicle.

**206 Changes in Basal Retinal Arterial Blood Flow before and after Intravitreal****207 Injection of the Gliotoxic Compound**

208 To determine the effect of the gliotoxic compound on basal retinal circulation, we  
209 measured the basal RBF before and 24 hours after intravitreal injection of a 60-mM  
210 concentration of LAA (n=4) in the same animals.

**211 Effects of a nNOS Inhibitor in LAA-treated eyes**

212 We showed previously that increases in RBF during flicker stimulation were attenuated  
213 after intravitreal injection of L-NPA (5 mM), a selective neuronal NO synthase (nNOS)  
214 inhibitor,<sup>26</sup> suggesting that nNOS contributes to regulation of the retinal circulation  
215 during flicker stimulation. To determine whether the decrease in RBF in response to  
216 flicker stimulation in LAA (60 mM)-treated eyes resulted from reduced NO by nNOS in  
217 retinal glial cells, we measured the RBF in response to flicker stimulation in LAA (60  
218 mM)-treated eyes 2 hours after intravitreal L-NPA injection (5 mM). L-NPA was  
219 injected 22 hours after LAA to confirm the maximal responses of LAA and L-NPA.

**220 Immunohistochemistry**

221 For whole-mount assessment, the eyes were enucleated and fixed in 1%  
222 paraformaldehyde for 1 hour. The retina was blocked and permeabilized in 5% goat  
223 serum with 0.3% Triton (Wako Pure Chemical Industries, Ltd., Osaka, Japan) in PBS  
224 for 1 to 2 hours. The retinas were transferred to primary antibodies diluted in block  
225 solution and incubated for 1 hour at room temperature. The primary antibody was  
226 mouse anti-glial fibrillary acidic protein (GFAP)-cy3 antibody (1:400; Sigma-Aldrich,  
227 St. Louis, MO) and isolectin IB4 conjugated to Alexa Fluor 647 (1:200) (Invitrogen,  
228 Carlsbad, CA) was stained. Ok as changed? The slides were mounted (Dako, Tokyo,  
229 Japan) and observed for green (cy3) and red (Alexa Fluor 647) staining and analyzed

230 with a fluorescence microscope (Fluoview FV 1000, Olympus, Tokyo, Japan).  
231 Photoshop CS 6 (Adobe Systems, Inc., Tokyo) was used to quantify the GFAP  
232 expression. The mean densities of three sites ( $300 \times 300 \mu\text{m}$ ) for each group were  
233 selected randomly in the observed area about 3 mm superior to the center of the optic  
234 nerve head (ONH) and measured, and the averages were compared.

### 235 **Histologic Examination**

236 To determine the gliotoxic effects of LAA, histologic examinations were performed 24  
237 hours after intravitreal injection of LAA 60 mM or 0.01N HCl. The enucleated eyes  
238 were fixed in 2% paraformaldehyde-2.5% glutaraldehyde in 10 mM PBS for 3 hours,  
239 then fixed in 4% paraformaldehyde, and embedded in paraffin. A transverse section of  
240 each retina ( $5 \mu\text{m}$ ) was cut parallel to the medullary rays of the ONH. The section of the  
241 retina was stained with hematoxylin and eosin (HE) and examined by light microscopy.  
242 To evaluate the retinal neural damage, the thicknesses of the ganglion cell layer (GCL),  
243 inner nuclear layer (INL), and outer nuclear layer (ONL) were measured in transverse  
244 sections. For this analysis, three light photomicrographs (magnification,  $\times 400$ ) were  
245 taken in a masked fashion about 3 mm superior to the center of the ONH. The thickness  
246 of each layer was averaged for each eye to obtain data for statistical analysis.

### 247 **ERG Recording and Analysis**

248 To determine the selective gliotoxicity of LAA on the retinal function, ERGs were  
249 performed before and 24 hours after intravitreal injection of LAA (60 mM) or 0.01 N  
250 HCl as a solvent. A light-emitting diode light stimulator (LS-C, Mayo Corporation,  
251 Aichi, Japan) and Ganzfeld Dome, a data acquisition system, and AC amplifier (PuREC  
252 system, PC-100, Mayo Corporation) were used to record the ERGs. Before the ERG  
253 recordings, the cats were dark-adapted for 2 hours after mydriasis with 0.4%

254 tropicamide (Santen Pharmaceutical Co.). The ERG was performed under general  
255 anesthesia induced by sevoflurane; recordings were performed with a gold ring active  
256 electrode on the cornea, a gold dish negative electrode in the mouth, and the ground  
257 electrode on an earlobe by single flash stimulation. The flash stimulus intensity was 1.0  
258 cds/m<sup>2</sup>. Bandpass filters were set at 0.3 to 500 Hz and the amplifier gain was set at  
259 x10,000 for the a- and b-waves. The amplitudes and the implicit times of the a- and  
260 b-waves were measured. All waveforms were analyzed by the PuREC system. We  
261 performed ERGs before and 24 hours after intravitreal injection of LAA at 60 mM  
262 (n=7) or 0.01 N HCl (n=7) as a control, and the amplitudes and the implicit times of the  
263 a- and b-waves of LAA-treated eyes were compared with those of the controls.

#### 264 **Statistical Analysis**

265 All data are expressed as the mean percentage  $\pm$  standard error of the mean. The  
266 vasodilator responses were calculated as the percentage increases of the RBF from  
267 baseline. For statistical analysis, we used analysis of variance (ANOVA) for repeated  
268 measurements, followed by post hoc comparison with the Dunnett procedure. Group  
269 comparisons of the RBF, histologic examinations, and ERGs were performed using the  
270 Mann-Whitney U-test or Wilcoxon signed-rank test.  $P < 0.05$  was considered  
271 statistically significant.

272

## 273 **RESULTS**

### 274 **Effects of Gliotoxic Compound on RBF at Baseline and in Response to Intravitreal** 275 **Injection of BK**

276 Twenty-four hours after injection of LAA (60 mM), there were no significant  
277 changes in retinal (D, V, RBF) and systemic circulatory (pH, PaCO<sub>2</sub>, PaO<sub>2</sub>, HCO<sub>3</sub><sup>-</sup>,

278 MABP, or HR) parameters (n=6) (Table 2) or in the amplitude or elongation of the  
279 implicit time of the ERG a- and b-waves (n=7) (Table 3).

280 In the 20- and 60-mM LAA groups, increases in D, V, and RBF induced by  
281 intravitreal injection of BK were comparable to those in the control groups (Fig. 1).  
282 There were no significant changes in any systemic circulatory parameters (pH,  
283 PaCO<sub>2</sub>, PaO<sub>2</sub>, HCO<sub>3</sub><sup>-</sup>, MABP, or HR) before and 120 minutes after intravitreal  
284 injection of BK (data not shown).

### 285 **Effects of Gliotoxic Compound on RBF in Response to Flicker Stimulation**

286 After 3 minutes of 16-Hz flicker stimulation, the D, V, and RBF maximally increased by  
287  $5.9 \pm 1.2\%$ ,  $36.9 \pm 2.1\%$ , and  $53.5 \pm 2.5\%$ , respectively, in the control group. In the  
288 LAA groups, those changes were significantly lower; the D, V, and RBF maximally  
289 increased by  $4.5 \pm 1.0\%$ ,  $25.4 \pm 3.5\%$ , and  $37.1 \pm 5.4\%$ , respectively, in the 20-mM  
290 LAA group maximally increased by  $2.8 \pm 0.8\%$ ,  $12.1 \pm 3.3\%$ , and  $19.6 \pm 2.4\%$ ,  
291 respectively, in the 60-mM LAA group (Fig. 2). There were no significant changes in  
292 any systemic parameters (pH, PaCO<sub>2</sub>, PaO<sub>2</sub>, HCO<sub>3</sub><sup>-</sup>, MABP, or HR) before, during, and  
293 after flicker stimulation (data not shown). In the preliminary study, we confirmed the  
294 absence of significant differences in the increases in the RBF in response to the flicker  
295 stimuli between the 0.01 N HCl- and PBS-treated eyes (data not shown).

### 296 **Effects of nNOS Inhibitor L-NPA on Flicker-Evoked Increase in Retinal**

#### 297 **Circulation in LAA-Treated Eyes**

298 In LAA-treated eyes, intravitreal injection of L-NPA (5 mM) significantly reduced the  
299 flicker-induced increases in RBF compared with eyes treated with only LAA (Fig. 3).

300 Before and 2 hours after injection of L-NPA and during flicker stimulation, the systemic

301 parameters (pH, PaCO<sub>2</sub>, PaO<sub>2</sub>, HCO<sub>3</sub><sup>-</sup>, MABP, or HR) did not change significantly  
302 (data not shown).

### 303 **Histologic Examination**

304 Fig. 4 shows transverse retinal sections stained with HE. There were no apparent  
305 changes in morphology in the GCL, INL, or ONL in the LAA-treated eyes. A  
306 quantitative assessment of the effect of LAA on the GCL, INL, and ONL is shown in  
307 Table 4. There were no significant ( $P > 0.05$ ) differences in the thickness in each layer  
308 between the LAA-treated and control eyes.

### 309 **Immunohistochemistry**

310 To examine the effect of LAA, GFAP staining was assessed in the whole retina (Fig. 5).  
311 GFAP immunofluorescence histochemistry (green astrocytes) and binding of isolectin  
312 IB4 (red vessels) was performed on flat-mounted feline retinal preparations before (Fig.  
313 5A) and 24 hours after intravitreal injection of 60 mM of LAA (Fig. 5B). Compared  
314 with the control, mean densities of GFAP expression were significantly ( $P < 0.05$ )  
315 reduced in LAA-treated eyes (Table 5).

316

### 317 **DISCUSSION**

318 Many studies have reported that glial cells contribute to neurovascular coupling in the  
319 brain.<sup>30-35</sup> Metea and Newman reported that glial cells may contribute to neurovascular  
320 coupling in the rat ex vivo retina.<sup>6</sup> In that study, selective stimulation of glial cells  
321 resulted in both vasodilation and vasoconstriction, and light-evoked vasodilation was  
322 blocked when the purinergic antagonist suramin interrupted neuronal-to-glial signaling.<sup>6</sup>  
323 In the current study, though we did not observe decreases in the RBF, we showed that  
324 the increases in RBF during flicker stimulation were attenuated significantly by

325 intravitreal injection of LAA compared with the control (Fig. 2). These conflicting  
326 results may be due to differences in experimental methodology, i.e., the current study  
327 was an in vivo experiment in cats, whereas the previous report used ex vivo  
328 whole-mount rat retina. However, both studies clearly showed that retinal glial cells  
329 regulate RBF during flicker stimulation.

330       Although recent ex vivo animal studies have reported that the retinal glial cells  
331 may play a principal role in functional hyperemia,<sup>6,16</sup> it is unclear whether glial cells  
332 regulate basal blood flow in the in vivo retina. In the current study, there was no  
333 significant difference in the basal RBF between before and after intravitreal injection of  
334 LAA (Table 2). Although the current findings cannot fully answer the question, there are  
335 three plausible reasons for this result. First, glial cells do not help regulate basal blood  
336 flow in the retina; second, the retina has a compensatory mechanism for regulating basal  
337 blood flow after suppressed glial function; and third, the retinal glial cells are partially  
338 blocked by LAA at a concentration of 60 mM so that the basal RBF does not change.  
339 Further studies are needed to clarify whether retinal glial cells help regulate basal blood  
340 flow.

341       Previous studies have shown that NO plays an important role in flicker-induced  
342 vasodilation in animals<sup>4</sup> and humans.<sup>36</sup> Recently, we reported that L-NPA (5 mM), a  
343 selective nNOS inhibitor, reduced flicker-induced increases in RBF by a third of the  
344 baseline value in cats, meaning that two-thirds of the flicker-induced hyperemia is  
345 generated by NO by nNOS in neuronal and/or glial cells in the retina.<sup>26</sup> The current  
346 study confirmed that LAA (60 mM) as a gliotoxic compound reduced flicker-induced  
347 increases in the RBF by a third of the baseline value, indicating that two-thirds of the  
348 flicker-induced hyperemia is generated by the retinal glial cells. In addition, a

349 flicker-induced increase in RBF was abolished by double blocking with L-NPA (5 mM)  
350 and LAA (60 mM). These results suggested that flicker-induced hyperemia may be  
351 generated by three prominent vasodilatory factors: NO by the nNOS in neurons, NO by  
352 the nNOS in glial cells, and another vasodilatory factor in glial cells (Fig. 5). Indeed,  
353 some studies have reported that nNOS protein was expressed in neurons and glial cells  
354 in mammalian retina.<sup>37-42</sup> Moreover, in retinal functional hyperemia, there are several  
355 vasodilatory candidates in glial cells without NO from glial cells, such as prostaglandin  
356 E<sub>2</sub> (PGE<sub>2</sub>) and epoxyeicosatrienoic acids (EETs).<sup>32</sup> The current study did not confirm  
357 definitively that the retinal glial cells play a dominant role (at least accounting for  
358 two-thirds of the regulation in flicker-induced hyperemia) in regulating flicker-induced  
359 hyperemia in the retina. Further studies should determine the role of vasodilatory factors  
360 other than NO in glial cells in regulating flicker-induced hyperemia in the retina.

361 It is well known that pericytes cover a large fraction of the capillary surface in the  
362 brain. Vasoactive molecules such as NO, PGE<sub>2</sub>, or EETs in astrocytes may cause  
363 pericytic dilation in capillaries and increase cerebral blood flow in functional  
364 hyperemia.<sup>43</sup> In the retina, pericytes cover the capillary surface more extensively than in  
365 the brain,<sup>44</sup> indicating that the interaction between glial cells and pericytes may be more  
366 important in functional hyperemia in the retina than the brain. Moreover, Kornfield and  
367 Newman reported that flicker-evoked vasodilation depended on vessel size and depth in  
368 the retina.<sup>45</sup> Indeed, both pericytic loss and impaired glial activity in the retina are  
369 detected before DR appears clinically and then the diminished response in  
370 flicker-evoked vasodilation is observed.<sup>46,47</sup> In the current study, suppression of the  
371 flicker-evoked increase in blood V was greater compared with that in vessel D in  
372 LAA-treated eyes. Because blood V in the retinal arterioles measured by LDV may

373 reflect the entire hemodynamics in the retinal vasculature including the downstream  
374 arterioles and capillaries, the current findings suggested that capillaries and not retinal  
375 arterioles may be primarily responsible for controlling the retinal circulation in  
376 flicker-induced hyperemia in the retina, which was mediated by glial cell activity.

377 In the present study, there were no significant changes in the implicit time of the  
378 ERG a- and b-waves after intravitreal injection of LAA at a concentration of 60 mM  
379 (Table 3). Although Welinder et al. reported that the amplitude of the ERG b-wave  
380 decreased in rabbit eyes injected with LAA<sup>48</sup>, they used a high concentration of LAA  
381 (150 mM) greater than in our study. Indeed, another previous report showed that LAA  
382 at a concentration of 200 mM caused neural damage and significant affected the ERG  
383 b-wave at 24 hours in rabbits.<sup>17</sup> In our preliminary experiment, we also confirmed that  
384 LAA at a concentration of 200 mM caused a significant reduction in the amplitude of  
385 the ERG b-wave in cats (data not shown). However, some reports have suggested that  
386 the implicit time of the ERG b-wave was not prolonged significantly after injections of  
387 low concentrations of LAA despite changes in the Muller cells and astrocytes.<sup>19,20</sup> In  
388 fact, a recent immunohistochemistry evaluation found that LAA at a concentration of 60  
389 mM damaged the retinal glial cells, histologic evaluation showed intact neural cells, and  
390 there were no significant reduction of the ERG b-wave.<sup>17</sup> In addition, we also  
391 determined whether 60 mM of LAA injected intravitreally may have any toxic effects  
392 on the neurons, which was confirmed by ERG and histologic examination in the current  
393 study. Despite the morphologic changes in the glial cells after LAA (Fig. 5, Table 5), the  
394 implicit time and amplitudes of the ERG a- and b-waves (Table 3) and the thickness of  
395 the GCL, INL, and ONL (Table 4) did not change significantly after intravitreal  
396 injection of a 60-mM concentration of LAA compared with the control. In addition, the

397 increase in RBF induced by BK, which elicits endothelium-dependent, NO-mediated  
398 vasodilation in isolated porcine retinal arterioles,<sup>28</sup> did not change significantly after  
399 intravitreal injection of both concentrations of LAA (Fig. 1). These results suggested  
400 that LAA concentrations in the current study selectively damaged glial cells without  
401 hurting the neurons and retinal vasculature.

402       The current study had some limitations. First, we did not clarify the detailed  
403 molecular mechanism of how retinal glial cells regulate RBF in response to flicker  
404 stimulation. Although we recently found possible involvement of the retinal NO derived  
405 from nNOS in flicker-induced hyperemia in the retina in anesthetized cats,<sup>26</sup> the current  
406 findings that L-NPA further reduced flicker-induced hyperemia in the retina after LAA  
407 treatment may indicate that NO derived from nNOS in retinal neurons and retinal glial  
408 cells may be involved in the flicker-induced hyperemia in the retina. In addition,  
409 although it was suggested that one particular mechanism of neurovascular coupling in  
410 which glial cells release vasodilatory PGE<sub>2</sub> and/or EETs as the arachidonic acid  
411 metabolites produced by cyclooxygenase (COX) is a principal and perhaps dominant  
412 mechanism mediating functional hyperemia in the retina,<sup>5</sup> we did not examine the role  
413 of these molecules in flicker-induced hyperemia in the retina because there is no  
414 selective and specific blocker of COX that is only in the retinal glial cells. Second, the  
415 current results did not determine which retinal glial cells, the Müller glial cells or  
416 astrocytes, play a central role in retinal circulation in response to flicker stimulation,  
417 because it is difficult to suppress separately each cellular function using a gliotoxic  
418 compound, which affects both of them.<sup>19,20</sup> Third, although the current data did not  
419 provide a definitive explanation for the effect of general anesthesia, we previously  
420 found in a preliminary study that sevoflurane per se did not change the vessel D of

421 isolated porcine retinal arterioles (data not shown) and the changes in the concentration  
422 of pancuronium bromide did not alter the RBF in cats anesthetized with sevoflurane  
423 (data not shown).<sup>26</sup> Finally, we could not investigate to what degree the retinal glial  
424 cells contributed to the basal RBF, because it is difficult to quantify the degree of  
425 functional damages in the retinal glial cells after intravitreal injection of LAA at a  
426 concentration of 60 mM. To resolve this issue, more advanced techniques and research  
427 are needed in the future.

428       Impaired glial cellular activity is related to the pathogenesis of some ocular  
429 diseases, such as DR or glaucoma.<sup>9-12</sup> In addition, these ocular diseases also have  
430 impaired regulation of ocular blood flow and decreases in flicker-evoked retinal  
431 vasodilation.<sup>15,47,49,50</sup> Although it is unclear whether glial cell dysfunction or  
432 insufficiency of the retinal circulation is the initial pathogenetic event in these diseases,  
433 dysfunction of the retinal glial cells participates in progression in these diseases.  
434 Therefore, further basic and clinical studies are warranted to examine whether improved  
435 glial function may be a novel target for treating ocular vascular disorders.

436       In conclusion, we found for the first time that the flicker-induced hyperemia in the  
437 retina was decreased in LAA-treated eyes, suggesting that glial cells play a major role in  
438 regulating RBF in response to flicker stimulation. Our findings indicated that three  
439 prominent types of vasodilators, i.e., nNOS from neurons, nNOS from glial cells, and  
440 other vasodilatory factors from glia, may contribute to the phenomena (Fig. 5). Because  
441 it has been reported previously that glial cell dysfunction may be involved in the  
442 pathogenesis of DR and glaucoma,<sup>9-12</sup> clarifying the detailed mechanisms of glial cells  
443 in the retinal vasculature may provide a further understanding of the pathogenesis in  
444 these ocular disorders.

445 **References**

- 446 1. Roy CS, Sherrington CS. On the Regulation of the Blood-supply of the Brain. *J*  
447 *Physiol.* 1890;11:85-158 117.
- 448 2. Attwell D, Buchan AM, Charpak S, Lauritzen M, Macvicar BA, Newman EA.  
449 Glial and neuronal control of brain blood flow. *Nature.* 2010;468:232-243.
- 450 3. Riva CE, Logean E, Falsini B. Visually evoked hemodynamical response and  
451 assessment of neurovascular coupling in the optic nerve and retina. *Prog Retin Eye*  
452 *Res.* 2005;24:183-215.
- 453 4. Kondo M, Wang L, Bill A. The role of nitric oxide in hyperaemic response to  
454 flicker in the retina and optic nerve in cats. *Acta Ophthalmol Scand*  
455 1997;75:232-235.
- 456 5. Newman EA. Functional hyperemia and mechanisms of neurovascular coupling in  
457 the retinal vasculature. *J Cereb Blood Flow Metab.* 2013;33:1685-1695.
- 458 6. Metea MR, Newman EA. Glial cells dilate and constrict blood vessels: a  
459 mechanism of neurovascular coupling. *J Neurosci.* 2006;26:2862-2870.
- 460 7. Hernandez MR. The optic nerve head in glaucoma: role of astrocytes in tissue  
461 remodeling. *Prog Retin Eye Res.* 2000;19:297-321.

- 462 8. Bringmann A, Pannicke T, Grosche J, et al. Muller cells in the healthy and  
463 diseased retina. *Prog Retin Eye Res.* 2006;25:397-424.
- 464 9. Weinreb RN, Khaw PT. Primary open-angle glaucoma. *Lancet.*  
465 2004;363:1711-1720.
- 466 10. Lieth E, Barber AJ, Xu B, et al. Glial reactivity and impaired glutamate  
467 metabolism in short-term experimental diabetic retinopathy. Penn State Retina  
468 Research Group. *Diabetes.* 1998;47:815-820.
- 469 11. Chihara E, Matsuoka T, Ogura Y, Matsumura M. Retinal nerve fiber layer defect  
470 as an early manifestation of diabetic retinopathy. *Ophthalmology.*  
471 1993;100:1147-1151.
- 472 12. Bloodworth JM, Jr. Diabetic retinopathy. *Diabetes.* 1962;11:1-22.
- 473 13. Lasta M, Pemp B, Schmidl D, et al. Neurovascular dysfunction precedes neural  
474 dysfunction in the retina of patients with type 1 diabetes. *Invest Ophthalmol Vis*  
475 *Sci.* 2013;54:842-847.
- 476 14. Nguyen TT, Shaw JE, Robinson C, et al. Diabetic retinopathy is related to both  
477 endothelium-dependent and -independent responses of skin microvascular flow.

- 478 *Diabetes Care*. 2011;34:1389-1393.
- 479 15. Garhofer G, Zawinka C, Resch H, Huemer KH, Schmetterer L, Dorner GT.  
480 Response of retinal vessel diameters to flicker stimulation in patients with early  
481 open angle glaucoma. *J Glaucoma*. 2004;13:340-344.
- 482 16. Newman EA. Calcium increases in retinal glial cells evoked by light-induced  
483 neuronal activity. *J Neurosci*. 2005;25:5502-5510.
- 484 17. Shibata M, Sugiyama T, Kurimoto T, et al. Involvement of glial cells in the  
485 autoregulation of optic nerve head blood flow in rabbits. *Invest Ophthalmol Vis*  
486 *Sci*. 2012;53:3726-3732.
- 487 18. Mishra A, Hamid A, Newman EA. Oxygen modulation of neurovascular coupling  
488 in the retina. *Proc Natl Acad Sci U S A*. 2011;108:17827-17831.
- 489 19. Bonaventure N, Roussel G, Wioland N. Effects of DL-alpha-amino adipic acid on  
490 Muller cells in frog and chicken retinae in vivo: relation to ERG b wave, ganglion  
491 cell discharge and tectal evoked potentials. *Neurosci Lett*. 1981;27:81-87.
- 492 20. Pedersen OO, Karlsen RL. Destruction of Muller cells in the adult rat by  
493 intravitreal injection of D,L-alpha-amino adipic acid. An electron microscopic

- 494 study. *ExperEye Res.* 1979;28:569-575.
- 495 21. Nagaoka T, Sakamoto T, Mori F, Sato E, Yoshida A. The effect of nitric oxide on  
496 retinal blood flow during hypoxia in cats. *Invest Ophthalmol Vis. Sci.*  
497 2002;43:3037-3044.
- 498 22. Yoshida A, Feke GT, Mori F, et al. Reproducibility and clinical application of a  
499 newly developed stabilized retinal laser Doppler instrument. *Am J Ophthalmol*  
500 2003;135:356-361.
- 501 23. Feke GT, Goger DG, Tagawa H, Delori FC. Laser Doppler technique for absolute  
502 measurement of blood speed in retinal vessels. *IEEE T Bio Med Eng.*  
503 1987;34:673-680.
- 504 24. Nakabayashi S, Nagaoka T, Tani T, et al. Retinal arteriolar responses to acute  
505 severe elevation in systemic blood pressure in cats: role of endothelium-derived  
506 factors. *Exper Eye Res.* 2012;103:63-70.
- 507 25. Riva CE, Cranstoun SD, Mann RM, Barnes GE. Local choroidal blood flow in the  
508 cat by laser Doppler flowmetry. *Invest Ophthalmol Vis. Sci.* 1994;35:608-618.
- 509 26. Yoshioka T, Nagaoka T, Song Y, Yokota H, Tani T, Yoshida A. Role of neuronal

- 510 nitric oxide synthase in regulating retinal blood flow during flicker-induced  
511 hyperemia in cats. *Invest Ophthalmol Vis. Sci.* 2015;56(5):3113-20.
- 512 27. Ishikawa Y, Mine S. Aminoadipic acid toxic effects on retinal glial cells. *Jpn J*  
513 *Ophthalmol.* 1983;27:107-118.
- 514 28. Nagaoka T, Kuo L, Ren Y, Yoshida A, Hein TW. C-reactive protein inhibits  
515 endothelium-dependent nitric oxide-mediated dilation of retinal arterioles via  
516 enhanced superoxide production. *Invest Ophthalmol Vis. Sci.* 2008;49:2053-2060.
- 517 29. Sogawa K, Nagaoka T, Izumi N, Nakabayashi S, Yoshida A. Acute  
518 hyperglycemia-induced endothelial dysfunction in retinal arterioles in cats. *Invest*  
519 *Ophthalmol Vis. Sci.* 2010;51:2648-2655.
- 520 30. Koehler RC, Gebremedhin D, Harder DR. Role of astrocytes in cerebrovascular  
521 regulation. *J Appl Physiol.* 2006;100:307-317.
- 522 31. Zonta M, Angulo MC, Gobbo S, et al. Neuron-to-astrocyte signaling is central to  
523 the dynamic control of brain microcirculation. *Nature Neurosci.* 2003;6:43-50.
- 524 32. Harder DR, Alkayed NJ, Lange AR, Gebremedhin D, Roman RJ. Functional  
525 hyperemia in the brain: hypothesis for astrocyte-derived vasodilator metabolites.

- 526        *Stroke*. 1998;29:229-234.
- 527    33. Paulson OB, Newman EA. Does the release of potassium from astrocyte endfeet  
528        regulate cerebral blood flow? *Science*. 1987;237:896-898.
- 529    34. Mulligan SJ, MacVicar BA. Calcium transients in astrocyte endfeet cause  
530        cerebrovascular constrictions. *Nature*. 2004;431:195-199.
- 531    35. Filosa JA, Bonev AD, Nelson MT. Calcium dynamics in cortical astrocytes and  
532        arterioles during neurovascular coupling. *Circulation Res*. 2004;95:e73-81.
- 533    36. Dorner GT, Garhofer G, Kiss B, et al. Nitric oxide regulates retinal vascular tone  
534        in humans. *Am J Physiol Heart Circ Physiol*. 2003;285:H631-636.
- 535    37. Koch KW, Lambrecht HG, Haberecht M, Redburn D, Schmidt HH. Functional  
536        coupling of a Ca<sup>2+</sup>/calmodulin-dependent nitric oxide synthase and a soluble  
537        guanylyl cyclase in vertebrate photoreceptor cells. *EMBO J*. 1994;13:3312-3320.
- 538    38. Goureau O, Hicks D, Courtois Y, De Kozak Y. Induction and regulation of nitric  
539        oxide synthase in retinal Muller glial cells. *J Neurochem*, 1994;63:310-317.
- 540    39. Yamamoto R, Bredt DS, Snyder SH, Stone RA. The localization of nitric oxide  
541        synthase in the rat eye and related cranial ganglia. *Neuroscience*.

- 542 1993;54:189-200.
- 543 40. Osborne NN, Barnett NL, Herrera AJ. NADPH diaphorase localization and nitric  
544 oxide synthetase activity in the retina and anterior uvea of the rabbit eye. *Brain*  
545 *Res.* 1993;610:194-198.
- 546 41. Venturini CM, Knowles RG, Palmer RM, Moncada S. Synthesis of nitric oxide in  
547 the bovine retina. *Biochem Biophys Res Comm.* 1991;180:920-925.
- 548 42. Dawson TM, Brecht DS, Fotuhi M, Hwang PM, Snyder SH. Nitric oxide synthase  
549 and neuronal NADPH diaphorase are identical in brain and peripheral tissues.  
550 *Proceedings of the Natlional Academy of Sciences of the United States of America*  
551 *U S A.*1991;88:7797-7801.
- 552 43. Hall CN, Reynell C, Gesslein B, et al. Capillary pericytes regulate cerebral blood  
553 flow in health and disease. *Nature.* 2014;508:55-60.
- 554 44. Frank RN, Dutta S, Mancini MA. Pericyte coverage is greater in the retinal than in  
555 the cerebral capillaries of the rat. *Invest Ophthalmol Vis Sci.* 1987;28:1086-1091.
- 556 45. Kornfield TE, Newman EA. Regulation of blood flow in the retinal trilaminar  
557 vascular network. *J Neurosci.* 2014;34:11504-11513.

- 558 46. Barber AJ, Gardner TW, Abcouwer SF. The significance of vascular and neural  
559 apoptosis to the pathology of diabetic retinopathy. *Invest Ophthalmol Vis Sci.*  
560 2011;52:1156-1163.
- 561 47. Nguyen TT, Kawasaki R, Wang JJ, et al. Flicker light-induced retinal vasodilation  
562 in diabetes and diabetic retinopathy. *Diabetes Care.* 2009;32:2075-2080.
- 563 48. Welinder E, Textorius O, Nilsson SE. Effects of intravitreally injected  
564 DL-alpha-aminoadipic acid on the c-wave of the D.C.-recorded electroretinogram  
565 in albino rabbits. *Invest Ophthalmol Vis Sci.* 1982;23:240-245.
- 566 49. Moore D, Harris A, Wudunn D, Kheradiya N, Siesky B. Dysfunctional regulation  
567 of ocular blood flow: A risk factor for glaucoma? *Clin Ophthalmol.*  
568 2008;2:849-861.
- 569 50. Kohner EM, Patel V, Rassam SM. Role of blood flow and impaired autoregulation  
570 in the pathogenesis of diabetic retinopathy. *Diabetes.* 1995;44:603-607.  
571  
572  
573  
574  
575

576 **Legends**

577 **FIGURE 1.** Effect of LAA on the vasodilatory response to bradykinin. Three groups  
578 include five subjects each. The data are expressed as the mean percentage  $\pm$  standard  
579 error of the mean of the pre-injection levels. We used two-way factorial ANOVA  
580 followed by the Dunnett procedure to compare LAA (20 and 60 mM) with the control  
581 group.  $P < 0.05$  is considered statistically significant. There are no significant  
582 differences among the three groups. N.S., not significant; D, diameter; V, velocity; F,  
583 retinal blood flow.

584

585 **FIGURE 2.** Time course of the changes from baseline in retinal circulation in response to  
586 flicker stimulation in the following groups: 0.01N HCl (n=6) as a control, 20 mM of  
587 LAA (n=6), and 60 mM of LAA (n=6). (A) The black bar represents the period of  
588 flicker (3 minutes) (frequency 16 Hz, modulation depth 100%, dark adaptation time 2  
589 hours). The data are expressed as the mean percentage  $\pm$  standard error of the mean of  
590 baseline.  $*P < 0.05$  and  $^{\dagger}P < 0.05$  compared with a control group by two-way  
591 repeated-measures ANOVA followed by the Dunnett procedure. (B) Maximal changes  
592 from baseline in the retinal circulation in response to flicker stimulation in A. The data  
593 are expressed as the mean percentage  $\pm$  standard error of the mean of baseline.  $*P <$   
594  $0.05$  compared with a control group by one-way factorial ANOVA followed by the  
595 Dunnett procedure. D, diameter; V, velocity; F, retinal blood flow.

596

597 **Figure 3.** Effect of L-NPA (nNOS) inhibitor) on the flicker-evoked increase in retinal  
598 circulation in LAA-treated eyes. The data are expressed as the mean percentage  $\pm$   
599 standard error of the mean of baseline.  $*P < 0.05$  is considered significant. We used the

600 two-way factorial ANOVA followed by the Dunnett procedure to compare between  
601 before and 2 hours after intravitreal injection of L-NPA in eyes treated with 60 mM of  
602 LAA. Flicker-evoked increases in the retinal circulation 2 hours after intravitreal  
603 injection of L-NPA (5 mM) in eyes treated with 60 mM of LAA have decreased  
604 significantly compared with eyes treated with only 60 mM of LAA.

605

606 **Figure 4.** Photomicrographs of transverse sections of the retina stained with  
607 hematoxylin and eosin (HE). Each section was obtained from eyes with intravitreal  
608 injection of 0.01 N HCl as a control (A) and LAA at 60 mM. No apparent changes are  
609 observed in the ganglion cell layer (GCL), inner nuclear cell layer (INL), and outer  
610 nuclear layer (ONL) of the retina. Black bar = 50  $\mu$ m.

611

612 **Figure 5.** Immunohistochemistry of flat-mounted retina. Astrocytes are stained with  
613 anti- GFAP antibody (green) and vessels are stained with lectin IB4 (red). The retinas  
614 were dissected from eyes given an intravitreal injection of 0.01N HCl as a control (A)  
615 and LAA at a concentration of 60 mM (B). Compared with the control (A), the  
616 astrocytic processes in LAA-treated eyes (B) seem shorter and deformed. White bar =  
617 50  $\mu$ m.

618

619 **Figure 6.** Scheme of the mechanisms of flicker-induced hyperemia in the retina.  
620 Putative mechanisms of the flicker-induced hyperemia in the retina. Three prominent  
621 types of vasodilators may contribute to the phenomena.

622

623

624 **Tables**625 **Table 1.** Systemic and Ocular Parameters at Rest

	<b>Control</b> <b>(n=6)</b>	<b>LAA 20 mM</b> <b>(n=6)</b>	<b>LAA 60 mM</b> <b>(n=6)</b>
pH	7.42 ± 0.01	7.42 ± 0.01	7.43 ± 0.01
PaCO <sub>2</sub> , mmHg	27.2 ± 1.1	26.1 ± 0.8	26.7 ± 0.2
PaO <sub>2</sub> , mmHg	140.3 ± 5.9	140.8 ± 4.9	139.6 ± 0.7
HCO <sub>3</sub> <sup>-</sup> , mmol/l	17.0 ± 0.5	16.8 ± 0.4	16.6 ± 0.1
MABP, mmHg	129.0 ± 2.7	127.1 ± 2.2	128.0 ± 0.7
HR, beats/min	145.0 ± 4.7	149.6 ± 3.9	142.3 ± 3.1
OPP, mmHg	114.0 ± 2.7	112.1 ± 2.2	114.9 ± 2.6
Diameter, μm	114.3 ± 2.2	116.0 ± 2.4	117.0 ± 1.5
Velocity, mm/sec	32.3 ± 2.1	30.2 ± 3.4	29.3 ± 2.4
RBF, μL/min	9.9 ± 0.3	9.6 ± 1.0	9.6 ± 0.9

626

627 Control means 0.01 N HCl as a solvent of LAA. Data are expressed as the mean ±

628 standard error of the mean. We used the Mann-Whitney U-test to compare the control

629 group with LAA groups (20 and 60 mM). *P* < 0.05 is considered significant. There are

630 no significant differences between the groups.

631

632 **Table 2.** Systemic and Ocular Parameters Before and 24 Hours after Intravitreal

633 Injection of LAA at 60 mM (n=4)

	<b>Before</b>	<b>After</b>
pH	7.42 ± 0.01	7.40 ± 0.01
PaCO <sub>2</sub> , mmHg	27.2 ± 1.1	28.6 ± 1.0
PaO <sub>2</sub> , mmHg	114.3 ± 2.6	111.8 ± 4.1
HCO <sub>3</sub> <sup>-</sup> , mmol/l	20.7 ± 0.7	20.1 ± 0.3
MABP, mmHg	103.2 ± 1.0	101.3 ± 1.3
HR, beats/min	121.0 ± 1.4	120.3 ± 4.3
OPP, mmHg	93.6 ± 0.9	91.7 ± 1.4
Diameter, μm	110.6 ± 2.9	110.7 ± 4.0
Velocity, mm/sec	31.1 ± 3.6	34.6 ± 2.9
RBF, μL/min	9.0 ± 1.3	10.2 ± 1.4

634

635 The data are the actual measured values. Each data point (before and after) was  
636 measured in the same individual. Data are expressed as the means ± standard error of  
637 the mean. To compare before with after injections of LAA (60 mM), we used the  
638 Wilcoxon signed-rank test.  $P < 0.05$  is considered significant. There are no significant  
639 ( $P > 0.05$ ) differences in any parameters between before and after injections. Before  
640 indicates before the intravitreal injections; after indicates 24 hours after the intravitreal  
641 injections.

642

643 **Table 3.** Effect of LAA on ERGs (n=7)

	Control	LAA (60 mM)	P Values
a-wave			
%Amplitude	103.2 ± 4.6	99.0 ± 5.2	0.38
%Implicit time	102.5 ± 4.2	99.6 ± 4.4	0.74
b-wave			
%Amplitude	96.0 ± 5.0	105.1 ± 6.5	0.52
%Implicit time	100.3 ± 3.1	101.9 ± 3.6	0.45

644

645 Data are expressed as the means ± standard error of the mean of values relative to the

646 baseline for 7 cats each. *P* values obtained using the Mann-Whitney U-test are shown.647 There are no significant ( $P > 0.05$ ) differences in any parameters between the groups.

648

649

650

651

652

653

654

655

656

657

658

659 **Table 4.** Thicknesses of the GCL,INL, and ONL before and 24 Hours after Intravitreal  
 660 Injection of LAA (60 mM) (n=5)

	<b>Control</b>	<b>LAA 60 mM</b>	<b><i>P</i> Value</b>
GCL ( $\mu\text{m}$ )	16.1 $\pm$ 0.8	15.9 $\pm$ 0.9	0.59
INL ( $\mu\text{m}$ )	17.8 $\pm$ 0.5	19.4 $\pm$ 0.7	0.16
ONL ( $\mu\text{m}$ )	46.6 $\pm$ 2.2	50.7 $\pm$ 3.0	0.28

661  
 662 Data are expressed as the mean  $\pm$  standard error of the mean for 5 cats. *P* values obtained  
 663 by Mann-Whitney U-test are shown. There are no significant differences ( $P > 0.05$ ) in  
 664 any layers between groups.

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680 **Table 5. Mean Densities (pixels/mm) of GFAP Expression in the Retina**

	<b>Control</b>	<b>LAA 60 mM</b>	<b><i>P</i> Value</b>
Mean density, pixels/mm	184305.5 ± 26600.2	27675.6 ± 3190.5	0.03

681

682 The mean densities of GFAP expression in astrocytes were compared quantitatively  
683 between two groups. Compared with the control, the mean densities of GFAP  
684 expression are significantly ( $P = 0.03$ ) reduced in LAA-treated eyes analyzed using the  
685 Mann-Whitney U-test. Data are expressed as mean ± standard error of the mean in two  
686 groups.

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709 **Supplemental Tables**710 **Supplemental Table 1.** Effect of BK on Systemic Parameters in Figure 2 (n=5)

	<b>Before</b>	<b>120 min</b>
pH	7.40 ± 0.02	7.41 ± 0.01
PaCO <sub>2</sub> , mmHg	27.9 ± 1.8	29.6 ± 1.5
PaO <sub>2</sub> , mmHg	107.4 ± 4.2	110.0 ± 3.8
HCO <sub>3</sub> <sup>-</sup> , mmol/l	17.3 ± 0.3	17.5 ± 0.5
MABP, mmHg	114.5 ± 5.0	111.4 ± 4.8
HR, beats/min	133.7 ± 5.1	132.0 ± 3.5
OPP, mmHg	101.5 ± 2.2	99.3 ± 2.6

711

712 Data are expressed as the mean ± standard error of the mean. Before indicates before the  
 713 intravitreal injections; 120 minutes indicates 120 minutes after the intravitreal injections.

714 The number of animals is 5 in each group. There are no significant ( $P = 0.05$ ) differences  
 715 in all parameters between before and 120 minutes after injections.

716

717

718

719

720

721

722

723

724

725

726 **Supplemental Table 2.** Effect of L-NPA on systemic Parameters in Figure 3 (n=5)

	<b>Before</b>	<b>120 min</b>
pH	7.41 ± 0.01	7.43 ± 0.01
PaCO <sub>2</sub> , mmHg	26.5 ± 1.4	26.4 ± 1.7
PaO <sub>2</sub> , mmHg	108.4 ± 3.1	108.4 ± 3.8
HCO <sub>3</sub> <sup>-</sup> , mmol/l	16.5 ± 0.3	16.4 ± 0.4
MABP, mmHg	108.2 ± 3.6	108.6 ± 4.7
HR, beats/min	131.0 ± 4.7	131.0 ± 5.0
OPP, mmHg	98.1 ± 2.6	98.5 ± 2.7

727

728 Data are expressed as the mean ± standard error of the mean. Before indicates before the  
 729 intravitreal injections; 120 minutes indicates 120 minutes after the intravitreal injections.

730 The number of animals is 5 in each group. There are no significant ( $P = 0.05$ ) differences  
 731 in all parameters between before and 120 minutes after injections.

732

733

734

735

736

737

738

739


740

741

742


743 **Figures**

**Figure 1.**




744

**Figure 2A.**




**Figure 2B.**




745

**Figure 3.**




746

Figure 4.




747

Figure 5.



748

Figure 6.



749